Related Experiment Video

Updated: Jul 4, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.6K

The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19

Lauren E Merz1, Annemarie E Fogerty2

  • 1Dana-Farber Cancer Institute, Boston.

NEJM Evidence
|February 6, 2024
PubMed

Insights

Coronavirus disease 2019 (Covid-19) involves complex interactions leading to thrombosis, including venous thromboembolism (VTE) and microthrombi. These thrombotic events contribute to organ damage and mortality, with rates evolving alongside Covid-19 variants and treatments.

Area of Science:

  • Medical Science
  • Immunology
  • Hematology

Background:

  • Thrombosis in Covid-19 patients arises from intricate interplay of immune, complement, fibrinolytic, endothelial, and coagulation systems.
  • Microthrombi formation is linked to end-organ damage, including acute respiratory distress syndrome and kidney dysfunction, and increased mortality.

Discussion:

  • Understanding the multifaceted mechanisms of Covid-19-associated thrombosis is crucial for patient management.
  • The evolving landscape of Covid-19, including new variants and therapeutic interventions, impacts the observed rates of venous thromboembolism (VTE).

Key Insights:

  • Covid-19 pathogenesis involves complex systemic interactions that promote thrombotic events.
  • Venous thromboembolism (VTE) and microthrombi are significant complications of Covid-19, contributing to severe outcomes.
  • The incidence of Covid-19 related VTE is dynamic and influenced by viral evolution and medical countermeasures.

Outlook:

  • Further research is needed to elucidate the precise molecular pathways driving thrombosis in Covid-19.
  • Developing targeted anticoagulant and anti-inflammatory strategies may mitigate thrombotic complications and improve patient prognosis.
  • Continued monitoring of VTE rates in the context of emerging Covid-19 variants and vaccination strategies is essential.

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.2K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.4K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
329
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.3K